dalteparin has been researched along with Metastase in 22 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "A total of 10 cancer patients with VTE treated with the LMWH enoxaparin at a standard dose of 1 mg/kg every 12 h were enrolled." | 2.80 | Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ( Gabizon, AA; Na'amad, M; Nasser, NJ; Weinberg, I, 2015) |
| "Patients with liver metastases from colorectal carcinoma who were scheduled for local ablation by radiotherapy (image-guided high-dose-rate interstitial brachytherapy) were prospectively randomized to receive PTX, UDCA and LMWH for 8 weeks (treatment) or no medication (control)." | 2.79 | Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. ( Damm, R; Gademann, G; Hass, P; Kropf, S; Mohnike, K; Pech, M; Ricke, J; Sangro, B; Seidensticker, M; Seidensticker, R; Wust, P, 2014) |
| "Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer." | 2.73 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). ( Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J, 2008) |
| "Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival." | 2.71 | The effect of low molecular weight heparin on survival in patients with advanced malignancy. ( Bos, MM; Büller, HR; Klerk, CP; Lensing, AW; Otten, HM; Piovella, F; Prandoni, P; Prins, MH; Richel, DJ; Smorenburg, SM; van Tienhoven, G, 2005) |
| "Heparin and its derivatives are known to attenuate cancer metastasis in preclinical models, but have not been used clinically due to adverse bleeding effects." | 1.42 | Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. ( Alyahya, R; Mousa, SA; Racz, M; Stain, SC; Sudha, T, 2015) |
| "Experimental metastasis of B16F10-VLA-4kd and B16F10 cells and interference by Tinzaparin were analysed in mice." | 1.40 | The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. ( Bendas, G; Borsig, L; Naggi, A; Ortmann, K; Roblek, M; Schlesinger, M; Torri, G, 2014) |
| "Experimental metastasis of MV3 cells in mice confirmed the relevance of VLA-4 for metastatic dissemination." | 1.38 | The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. ( Bendas, G; Casu, B; Naggi, A; Schlesinger, M; Schmitz, P; Torri, G; Zeisig, R, 2012) |
| "The pattern of breast cancer metastasis may be determined by interactions between CXCR4 on breast cancer cells and CXCL12 within normal tissues." | 1.34 | Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? ( Ali, S; Eldaly, H; Harvey, JR; Kirby, JA; Lennard, TW; Mellor, P, 2007) |
| " Clexane was also used for thromboembolic complications prophylaxis during performance of operative intervention (in 40 mg daily dosage during 7-12 days)." | 1.33 | [Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer]. ( Sukhoversha, OA, 2006) |
| " Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice." | 1.33 | Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. ( Choi, SH; Stevenson, JL; Varki, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Klerk, CP | 1 |
| Smorenburg, SM | 1 |
| Otten, HM | 1 |
| Lensing, AW | 1 |
| Prins, MH | 1 |
| Piovella, F | 1 |
| Prandoni, P | 1 |
| Bos, MM | 1 |
| Richel, DJ | 1 |
| van Tienhoven, G | 1 |
| Büller, HR | 1 |
| Simonis, D | 2 |
| Christ, K | 1 |
| Alban, S | 1 |
| Bendas, G | 5 |
| Roy, SF | 1 |
| Watson, P | 1 |
| Bouffard, D | 1 |
| Nasser, NJ | 1 |
| Na'amad, M | 1 |
| Weinberg, I | 1 |
| Gabizon, AA | 1 |
| Seidensticker, M | 1 |
| Seidensticker, R | 1 |
| Damm, R | 1 |
| Mohnike, K | 1 |
| Pech, M | 1 |
| Sangro, B | 1 |
| Hass, P | 1 |
| Wust, P | 1 |
| Kropf, S | 1 |
| Gademann, G | 1 |
| Ricke, J | 1 |
| Riess, H | 1 |
| Pelzer, U | 1 |
| Hilbig, A | 1 |
| Stieler, J | 1 |
| Opitz, B | 1 |
| Scholten, T | 1 |
| Kauschat-Brüning, D | 1 |
| Bramlage, P | 1 |
| Dörken, B | 1 |
| Oettle, H | 1 |
| Amirkhosravi, A | 2 |
| Mousa, SA | 4 |
| Amaya, M | 2 |
| Meyer, T | 1 |
| Davila, M | 1 |
| Robson, T | 1 |
| Francis, JL | 2 |
| Schlesinger, M | 3 |
| Schmitz, P | 3 |
| Zeisig, R | 1 |
| Naggi, A | 3 |
| Torri, G | 3 |
| Casu, B | 1 |
| Robert, F | 1 |
| Busby, E | 1 |
| Marques, MB | 1 |
| Reynolds, RE | 1 |
| Carey, DE | 1 |
| Sukhoversha, OA | 1 |
| Buckman, R | 1 |
| Monreal, M | 1 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Roncales, J | 1 |
| Vilaseca, B | 1 |
| Gerber, U | 1 |
| Schütze, N | 1 |
| Jüngel, E | 1 |
| Blaheta, R | 1 |
| Roblek, M | 1 |
| Ortmann, K | 1 |
| Borsig, L | 1 |
| Sudha, T | 2 |
| Yalcin, M | 1 |
| Lin, HY | 1 |
| Elmetwally, AM | 1 |
| Nazeer, T | 1 |
| Arumugam, T | 1 |
| Phillips, P | 1 |
| Noel-Savina, E | 1 |
| Sanchez, O | 1 |
| Descourt, R | 1 |
| André, M | 1 |
| Leroyer, C | 1 |
| Meyer, G | 1 |
| Couturaud, F | 1 |
| Alyahya, R | 1 |
| Racz, M | 1 |
| Stain, SC | 1 |
| Fritzsche, J | 1 |
| Kragh, M | 1 |
| Binderup, L | 1 |
| Vig Hjarnaa, PJ | 1 |
| Bramm, E | 1 |
| Johansen, KB | 1 |
| Frimundt Petersen, C | 1 |
| Stevenson, JL | 1 |
| Choi, SH | 1 |
| Varki, A | 1 |
| Harvey, JR | 1 |
| Mellor, P | 1 |
| Eldaly, H | 1 |
| Lennard, TW | 1 |
| Kirby, JA | 1 |
| Ali, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase[NCT00716898] | 25 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Evaluation of the Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity After Brachytherapy of Liver Metastases From Colorectal Carcinoma, Assessed in a Prospective Randomised Trial[NCT01149304] | Phase 2 | 22 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for dalteparin and Metastase
| Article | Year |
|---|---|
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Humans; Inj | 2005 |
Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.
Topics: Aged; Aged, 80 and over; Enoxaparin; Factor Xa; Female; Glucuronidase; Humans; Male; Middle Aged; Ne | 2015 |
Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.
Topics: Aged; Aged, 80 and over; Brachytherapy; Colorectal Neoplasms; Enoxaparin; Female; Humans; Liver Neop | 2014 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2008 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2003 |
17 other studies available for dalteparin and Metastase
| Article | Year |
|---|---|
Affinity and kinetics of different heparins binding to P- and L-selectin.
Topics: Anticoagulants; Enoxaparin; Humans; Kinetics; L-Selectin; Nadroparin; Neoplasm Metastasis; P-Selecti | 2007 |
Bullous hemorrhagic dermatosis.
Topics: Anticoagulants; Diagnosis, Differential; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Midd | 2020 |
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Enoxaparin; Hum | 2010 |
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Topics: Acetylation; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Cell Adhesion; Cell Line, T | 2012 |
[Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer].
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enoxapari | 2006 |
Metronomic cyclophosphamide and methotrexate for breast cancer: enhanced efficacy by adding dalteparin and low-dose prednisone?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality T | 2011 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |
Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Topics: Anticoagulants; Carcinogenesis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cysteine-Rich Protei | 2013 |
The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Topics: Animals; Anticoagulants; Cell Adhesion; Cell Line, Tumor; Cell Movement; Heparin, Low-Molecular-Weig | 2014 |
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Deoxycyt | 2014 |
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W | 2015 |
Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models.
Topics: Animals; Anticoagulants; Disease Models, Animal; Female; Heparin; Heparin, Low-Molecular-Weight; Hum | 2015 |
Binding between heparin and the integrin VLA-4.
Topics: Acoustics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biosensing Techniques; Cell Ad | 2009 |
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Topics: Animals; Endothelium, Vascular; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Lipoprot | 2003 |
Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.
Topics: Animals; Anticoagulants; Carbohydrate Sequence; Cell Line, Tumor; Female; Heparin, Low-Molecular-Wei | 2005 |
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Topics: Animals; Anticoagulants; Cell Line, Tumor; Disaccharides; Factor Xa; Fibrinolytic Agents; Fondaparin | 2005 |
Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Calcium; Cell Line, Tumor; Chemokine CXCL12; Chemokines, | 2007 |